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ABSTRACT 28 
BACKGROUND: 29 
Antimicrobial stewardship aims to optimise antibiotic use and minimise selection of antimicrobial 30 
resistance. The methodological quality of published studies in this field is unknown. 31 
 32 
OBJECTIVES: 33 
Our objective was  to perform a comprehensive systematic review of antimicrobial stewardship research 34 
design and identify features which limit validity and translation of research findings into clinical practice. 35 
 36 
DATA SOURCES: 37 
The following online database was searched: PubMed. 38 
 39 
STUDY ELIGIBILITY CRITERIA: 40 
Studies published between January 1950 and January 2017, evaluating any antimicrobial stewardship 41 
intervention in the community or  hospital setting, without restriction on study design or outcome. 42 
 43 
METHODS: 44 
We extracted data on pre-specified design quality features and factors that may influence design choices 45 
including: (1) clinical setting, (2) age group studied, (3) when the study was conducted, (4) geographical 46 
region and (5) financial support received. 47 
 48 
RESULTS: 49 
The initial search yielded 17,382 articles; 1,008 were selected for full-text screening, of which 825 were 50 
included. Most studies (675/825, 82%) were non-experimental and 104 (15%) used interrupted time 51 
series analysis, 41 (6%) used external controls and 19 (3%) used both. Studies in the community setting 52 
fulfilled a median of 5/10 quality features (IQR 3-7) and 3 (IQR 2-4) in the hospital setting. Community 53 
setting studies (25%, 205/825) were significantly more likely to use randomisation (OR 5.9 (95%CI 3.8-54 
9.2)), external controls (OR 5.6 (95%CI 3.6-8.5)) and multiple centres (OR 10.5 (95%CI 7.1-15.7)). From 55 
all studies, only 48% (398/825) reported clinical and 23% (190/825) reported microbiological outcomes.  56 
Quality did not improve over time.  57 
 58 
CONCLUSIONS: 59 
Overall quality of antimicrobial stewardship studies is low and has not improved over time. Most studies 60 
do not report clinical and microbiological outcome data. Studies conducted in the community setting were 61 
associated with better quality. These limitations should inform the design of future stewardship 62 
evaluations so that a robust evidence base can be built to guide clinical practice.    63 
INTRODUCTION 64 
Antimicrobial resistance (AMR) is increasing globally and is a substantial threat to human health[1]. There 65 
is a clear relationship between antibiotic exposure and AMR both in populations [2] and individual patients 66 
[3]. An estimated 30% of human antibiotic use may be unnecessary and healthcare systems around the 67 
world are aiming to achieve substantial reductions in unnecessary antibiotic prescribing. The term 68 
‘antimicrobial stewardship’ is used to describe use of antibiotics which balances the need for effective 69 
individual treatment against the longer-term, societal impact of antibiotic use on antibiotic resistance[4]. 70 
Interventions to improve antimicrobial stewardship are usually multifaceted and include periodic or 71 
individual patient audit and feedback, decision support, education (educational meetings, educational 72 
materials), and antimicrobial formulary restriction[5]. 73 
Recognition of the threat posed by AMR and the need to optimise antibiotic prescribing has driven an 74 
exponential increase in the publication of studies evaluating antimicrobial stewardship interventions over 75 
the last 20 years[6]. Previous systematic reviews have synthesised this evidence with the aim of making 76 
recommendations for practice[5,7–12].  These have, appropriately, considered studies with the lowest 77 
possible risk of bias but have excluded >50% of published studies in which methodological quality falls 78 
below Effective Practice and Organisation of Care (EPOC) criteria[13]. Because the minority of studies 79 
are of sufficient quality, many areas of practice rely on a weak evidence base [8]; conducting studies 80 
which do not inform practice is a waste of time and valuable resources [5,12].  81 
Journals are beginning to report the minimum standards for antimicrobial stewardship studies to be 82 
published [14]; however, there remains a need for consensus on how to design, analyse and report 83 
studies evaluating interventions to improve antibiotic prescribing. This would optimise use of valuable 84 
resources and strengthen the evidence base in this field. Currently, no overview exists of how 85 
antimicrobial stewardship evaluations are designed. We conducted a systematic review of antimicrobial 86 
stewardship evaluations with the aim of identifying areas in stewardship evaluation most in need of 87 
improvement,  to increase validity and translation of research findings into clinical practice. 88 
 89 
METHODS 90 
Search strategy 91 
We searched PubMed for studies evaluating antimicrobial stewardship interventions between January 92 
1950 and January 2017. The search strategy (appendix 1) was designed to be as broad as possible. 93 
Inclusion criteria were: any study evaluating an antimicrobial stewardship intervention, without restriction 94 
on the type of intervention studied and what outcomes were evaluated. Studies were excluded if they 95 
were (1) not in English, (2) case-reports, (3) focused mainly on HIV or (4) narrative or systematic reviews. 96 
All studies were screened by one author (VAS, CHvW, JI, KH or IvH). In case of duplicate publications, 97 
only the original article was included. A random selection of 700 (~4% of total) studies were assessed by 98 
a second author (VAS, CHvW, JI, KH or IvH). Uncertainties about the inclusion of studies was resolved by 99 
discussion.   100 
 101 
Data extraction 102 
Studies fulfilling the inclusion criteria were identified by screening on title and abstract. All selected 103 
studies then underwent full-text evaluation by one author (VAS, CHvW, JI, KH or IvH) against the 104 
inclusion and exclusion criteria and data was subsequently extracted using a standard data extraction 105 
template (appendix 2). Data were extracted on study characteristics (i.e. title, authors, year of 106 
publication), design quality features, and factors possibly associated with methodological quality. If no 107 
funding was reported it was assumed that studies received no financial support. Authors were not 108 
contacted in case data were missing or incomplete. A random selection of 10% of the studies were 109 
extracted by a second author. We followed the PRISMA criteria for the reporting of systematic reviews 110 
(appendix 3) [15]. 111 
 112 
Selection of quality features, and factors associated with quality 113 
In February 2017 we established an international Consensus Working Group funded by the Joint 114 
Programming Initiative on Antimicrobial Resistance (JPIAMRWG-010) to develop recommendations on 115 
the design, analysis and reporting of antimicrobial stewardship evaluations. The working group 116 
coordinators (VAS, CHvW, ML, ASW, MB) invited members to the consensus group based on their 117 
expertise on antimicrobial stewardship and/or trial methodology, ensuring that all key clinical areas 118 
(primary care, secondary care, intensive care medicine and paediatrics) were represented.  The 119 
consensus group agreed that a review to identify areas in stewardship evaluation most in need of 120 
improvement to increase validity and translation of research findings into clinical practice was required. 121 
For this purpose, existing quality scores were not applicable because these focus solely on 122 
methodological quality. The group selected quality features and factors likely to underlie design quality 123 
and features based on plenary group discussion during the consensus meeting. Ten quality features were 124 
selected for assessment: (1) randomized research design used, (2) external control group assessed, (3) 125 
multiple centres used, (4) sustainability of the intervention sufficiently assessed (≥12 months), (5) sample 126 
size calculation reported, (6) prospective data collection, (7) correction for confounding factors, (8) 127 
primary outcome defined and reported, (9) clinical outcome reported, and (10) microbiological outcome 128 
reported.. Selected factors likely to underlie design quality features were (a) the clinical setting 129 
(community versus hospital), (b) age group studied (studies including children versus adults, or both), (c) 130 
year when study was conducted (newer versus older studies, categorised at approximate quintiles: 1977-131 
2004, 2005-2010, 2011-2013, 2014-2015, 2016-2017) (d) geographical region, and (e) financial support. 132 
The quality features and corresponding categorizations are shown in table S1. 133 
 134 
Statistical analysis 135 
Descriptive statistics were used to describe the quality features of included studies. Differences stratified 136 
by subgroup were displayed using spider graphs (Microsoft Excel, version 2010). To assess the 137 
independent relationship between factors and quality features we performed multivariable logistic 138 
regression models with backward stepwise selection (exit p-value >0.10), presenting odds ratios and 95% 139 
confidence intervals in a heat map displaying the strength of the association (Microsoft Excel, version 140 
2010). Analyses were performed using the Statistical Package for the Social Sciences for Windows 141 
(Version SPSS 21.0.0.0). 142 
 143 
RESULTS 144 
The initial search yielded 17,382 articles. After title and abstract screening, 1,008 articles were selected 145 
for full-text screening (figure 1). Of these, 183 were excluded leaving 825 articles for full assessment 146 
(appendix 4). Among 700 randomly selected articles that were screened by a second author, 640/700 147 
(91%) were excluded by both authors, 23/700 (3.3%) were selected for inclusion by both authors, 13/700 148 
(1.8%) were selected for inclusion by only the first author, and 24/700 (3.4%) were selected for inclusion 149 
by only the second author, resulting in a percentage agreement after title/abstract screening of 95%, with 150 
a moderate interobserver agreement (Cohen’s kappa: 0.53). After discussion of the full text articles, 151 
consensus about inclusion was reached in 99.5% (696/700) of the selected articles. From the 3.4% 152 
(24/700) studies that were newly identified by a second author, 7/700 (1.0%) were considered correct 153 
inclusions after discussion. Therefore, the low proportion of missed papers justified not screening in 154 
duplicate. Among the 83 articles selected for double data-extraction by a second author, the percentage 155 
agreement per variable ranged from 91%-100%, with all the quality features showing an agreement of 156 
≥95%. 157 
 158 
Characteristics of included studies 159 
A total of 825 studies were included, In the community setting, most studies were multicentre (72%, 160 
148/205) and the commonest study designs were before-after studies without an interrupted time-series 161 
(ITS) analysis (23%, 48/205), randomised controlled trials (14%, 28/205), and parallel cluster randomised 162 
trials (15%, 30/205)(Table 1). Among the included studies in the hospital setting, most were single centre 163 
(84%, 519/620) and the commonest study designs were before-after studies without an ITS analysis 164 
(59%, 365/620), before-after studies with an ITS analysis (13%, 82/620), and cohort studies without a 165 
control group (12%, 75/620). Among the before-after studies without an ITS analysis, the majority were 166 
single centre (86%, 352/411), and retrospective (58%, 239/411). In the 86 (10%) cluster randomised 167 
studies a median of 28 clusters were randomised, with 57% (49/86) randomising ≥20 clusters, 28% 168 
(24/86) randomising <15 clusters, 21% (18/86) randomising <10 clusters, and 9% (8/86) randomising <5 169 
clusters. In the hospital setting, 13% (2/13) randomised ≥20 clusters, while in the community setting 65% 170 
(64/71) randomised ≥20 clusters. A minority of studies were conducted in children (12%, 101/825). Both 171 
in the community and the hospital setting, most studies did not target a specific disease or syndrome 172 
(31%, 63/205, 55% 324/620, respectively) or specific antibiotic class (86%, 177/205, 69% 427/620, 173 
respectively). The majority of interventions were bundles (57%, 470/825). Commonest interventions in the 174 
community setting included education (73%, 149/205), audit with periodic feedback (29%, 59/205), and 175 
clinical decision support 15% (31/205). In the hospital setting, commonest interventions included 176 
education 42% (260/620), audit and feedback on an individual patient level (40%, 245/620), restriction 177 
(18%, 113/620), and clinical decision support (18%, 112/620). Both in the community and hospital setting, 178 
virtually all included studies reported process measure outcomes (99%, 818/825) (Table 2). Both in the 179 
community setting and the hospital the most commonly reported process measures included the 180 
proportion of patients treated with antibiotics (59%, 121/205, 21%, 131/620), costs/cost-effectiveness 181 
(18%, 36/205, 32%, 200/620, respectively), appropriateness (17%, 34/205, 29%, 178/620, respectively), 182 
and defined daily doses (17%, 34/205, 25%, 156/620, respectively). In the community setting, commonest 183 
reported clinical outcomes were revisits (11%, 22/205), clinical cure (6%,12/205), and infection (5%, 184 
10/205), while in the hospital setting these were mortality (32%, 302/620), length of stay (32%, 201/620), 185 
and hospital readmissions (12%, 76/620).  186 
 187 
Quality features 188 
The percentage of studies including each quality feature is shown in Table 3. Studies in the community 189 
setting fulfilled a median of 5 quality features (IQR 3-7), while studies in the hospital setting fulfilled 3 (IQR 190 
2-4). None fulfilled all 10 quality features. In the community setting 2% (4/205) fulfilled 9, 16% (33/205) 191 
fulfilled at least 8, and 35% (72/205) fulfilled at least 7 quality indicators. In the hospital setting 1% (4/620) 192 
fulfilled 9, 3% (19/620) fulfilled 8, and 6% (37/620) fulfilled 7 quality indicators. Of note, there were 193 
substantial differences between studies which did and did not use randomised designs to the extent to 194 
which other quality features were present. Among the 150 randomised studies, all used an external 195 
control group, 71% (107/150) included multiple centres, 64% (97/150) reported a sample size calculation 196 
and 96% (144/150) collected data prospectively. In contrast, among the non-randomised studies, 12% 197 
(78/675) used an external control group, 21% (142/675) included multiple centres, 11% (76/675) reported 198 
a sample size calculation and 43% (288/675) collected data prospectively. 199 
 200 
Factors associated with design quality 201 
Design quality was considerably better in almost all quality aspects of community versus hospital setting 202 
studies (Figure S1A), with more use of randomised designs (46% vs. 9%), external controls (63% vs. 203 
16%), sample size calculations (38% vs. 15%), prospective data collection (70% vs. 46%), correction for 204 
confounding (55% vs. 25%), use of a defined primary outcome (57% vs. 44%), and involvement of 205 
multiple centres (72% vs. 16%). However, community setting studies less often reported clinical (30% vs. 206 
54%) and microbiological (8% vs. 28%) outcomes. Community setting remained significantly associated 207 
with all these factors in multivariable models (Table 4). From the studies that reported financial support, 208 
20% (53/264) were industry funded, and 84% (221/264) were publicly funded. Studies with financial 209 
support were of higher methodological quality than studies without (Figure S1B), as they more frequently 210 
used randomised designs (31% vs. 7%), external controls (34% vs. 8%), sample size calculations (33% 211 
vs. 11%), prospective data collection (63% vs 43%), correction for confounding (46% vs. 21%), a defined 212 
primary outcome (56% vs. 39%), and involved multiple centres (46% vs. 16%). Financial support 213 
remained significantly associated with these factors in multivariable models (Table 4). In addition, 214 
financial support increased the frequency of reporting clinical outcomes in multivariable models. There 215 
was little change in design quality over time, other than a decrease in the proportion of studies with 216 
prospective data collection (77% in 1977-2004, 67% in 2005-2010, 42% in 2011-2013, 40% in 2014-217 
2015, 39% in 2016-2017) and an increase in studies reporting a clinical outcome (39% in 1977-2004, 218 
44% in 2005-2010, 44% in 2011-2013, 53% in 2014-2015, 59% in 2016-2017)) (Figure S1D). These 219 
outcomes were significantly associated with calendar time in multivariable models (Table 4), and sample 220 
size calculations were independently reported more in later studies. The decrease in studies with 221 
prospective data collection is most prominent in studies in the hospital setting (Table S2). There were no 222 
large differences between studies performed in children versus adults (Figure S1C). Geographical region 223 
was independently associated with randomised designs, using an external control, prospective data 224 
collection, performing sample size calculations, reporting a primary, clinical or microbiological outcome, 225 
and being multicentre (Table 4). 226 
 227 
DISCUSSION 228 
In previous systematic reviews of antimicrobial stewardship evaluations, many studies have been 229 
excluded due to not fulfilling minimal methodological quality criteria. We have undertaken the first 230 
comprehensive systematic review focusing on describing quality, rather than excluding studies based on 231 
quality, to facilitate formulating recommendations for improvement. In addition, we evaluated quality 232 
features required for validity and translation into practice instead of focusing solely on methodological 233 
quality. Our systematic review revealed that the design quality of antimicrobial stewardship evaluations is 234 
low, with only a minority of studies reporting clinical and microbiological outcome data. Design quality is 235 
considerably better in studies performed in the community setting. 236 
We find published evaluations provide a striking lack of evidence for the clinical and microbiological 237 
impacts of antimicrobial stewardship interventions. The majority of studies focus exclusively on process 238 
measures. While it is clearly essential to establish whether an intervention is effective in changing 239 
antibiotic use, reporting clinical outcomes is crucial to assess the safety of antimicrobial stewardship 240 
interventions [16,17]. The clinical outcomes reported often utilise routinely collected data, which may 241 
explain the differences between the community and hospital setting. In particular, in the hospital setting, 242 
commonly used clinical outcomes are mortality and length of hospital stay [18,19]. As indicated by the 243 
observed time trends, these outcomes are being used with increasing frequency, probably because 244 
extraction of relevant data from electronic health records is becoming more feasible. Such routinely 245 
available data are not the most sensitive and patient-relevant outcomes. In the hospital setting, markers 246 
of early treatment response such as clinical stability may be preferable. In the community setting, repeat 247 
consultations, relapse of infection, and hospital admissions may be more relevant; yet data on these 248 
outcomes are not routinely collected [20–22].  249 
Very few stewardship studies report microbiological outcomes. This is  surprising given that reducing 250 
antimicrobial resistance is the ultimate goal of antimicrobial stewardship. However, this is consistent with 251 
a meta-analysis on the effect of stewardship interventions on infection and colonisation with antibiotic-252 
resistant bacteria and Clostridium difficile infections that showed the literature on this topic is sparse and 253 
dominated by low quality research [23]. Some authorities have called for stewardship evaluations to 254 
routinely include consideration of the impact of stewardship on resistance [24] but studies generally lack 255 
power to determine this. Relationships between antimicrobial exposure and resistance may be more 256 
efficiently established through specific mechanistic studies rather than within stewardship evaluations.  257 
Our analysis demonstrates that factors that would be expected to effect study design do, whiles others do 258 
not. The contrast between the community and hospital setting is striking in terms of the greater use of 259 
multicentre, randomised controlled designs.  One explanation could be that clusters required for cluster 260 
randomisation are more readily available in the community setting. In contrast, clinical outcomes and 261 
microbiological data are less readily available in the community setting. Retrospective study designs are 262 
therefore less feasible in the community setting.  263 
Financial support was associated with better design quality. In addition to the costs inherent to conducting 264 
multicentre, prospective studies with longer follow-up, the process of securing funding may drives careful 265 
consideration of study validity. Less than half of the stewardship studies reviewed reported external 266 
funding. However, our finding of an association between external funding and improved design quality 267 
underscore the necessity of external funding to support appropriate implementation and robust evaluation 268 
of antimicrobial stewardship programmes [25]. 269 
Our results show that there is no improvement of design quality over time, which is in contrast to previous 270 
reports[5,23]. This may be explained by our evaluation  and inclusion of all studies without a pre-selection 271 
on study design, while previous reviews only included adequate studies with interpretable data[5]. .  272 
In keeping with previous reports we find that the majority of antimicrobial stewardship studies used non-273 
randomised research designs, with before-after studies being the most prevalent. This quasi-experimental 274 
research design is commonly used for quality improvement projects. However, such studies are at risk 275 
from multiple forms of bias [16,24,26] and the Effective Practice and Organisation of Care (EPOC) criteria 276 
strongly discourages the inclusion of before-after studies without an ITS analysis in systematic 277 
reviews[13]. Incorporation of properly conducted ITS analysis into before-after studies has the potential to 278 
robustly control for time-dependent bias [27] but only 20% (104/515) of before-after studies we identified 279 
used ITS analysis. Moreover, it has been shown that contemporary ITS analyses are often performed 280 
with an insufficient number of data points [11].  281 
This systematic review has several strengths. First, our comprehensive search strategy gives a unique 282 
overview of the quality of studies evaluating antimicrobials stewardship interventions. Second, we used 283 
the PRISMA reporting guide for systematic reviews [15]. Third, the quality indicators and candidate 284 
factors were selected in a consensus procedure as part of a Joint Programming Initiative on Antimicrobial 285 
Resistance (JPIAMR) funded consensus group, which was selected to both include experts on the field of 286 
antimicrobial stewardship and trial methodology. Finally, this is the first comprehensive systematic review 287 
to determine the extent to which published antimicrobial stewardship evaluations include quality features 288 
required for validity and translation into practice .  289 
The limitations of our review were firstly, we only searched PubMed and excluded non-English studies, 290 
which makes it possible that antimicrobial stewardship studies indexed elsewhere and non-English 291 
studies were missed. However, if we compare the studies identified by our searching strategy with the 292 
largest community and hospital stewardship systematic reviews, only 6 studies were missed due to being 293 
indexed elsewhere and 11 due to being non-English. Therefore, this is likely to have had a minimal 294 
impact on the total results[5,12]. Secondly, the screening, inclusion, and data extraction was performed 295 
by only one investigator that could have resulted in studies being missed, wrongly included or 296 
misclassification of the extracted data. To estimate the amount of studies that might be missed, a 297 
proportion of the studies were screened and data was extracted by a second author. In this second 298 
round, we showed that the percentage of agreement was high, with a moderate interobserver agreement. 299 
Assuming that every disagreement in included studies would have inadvertently excluded a study (1% of 300 
700 studies reviewed twice), we may have missed a maximum of 104 inclusions in the other studies not 301 
screened twice. In a systematic review with meta-analysis the consequence of missing or wrongly 302 
including a single study could have a large impact on the pooled effect estimate. However, as we did not 303 
focus on the outcome of individual studies but rather on the design quality of many studies, given the 304 
large number of studies included, it is unlikely that the missed studies would have changed the 305 
conclusions. And lastly, the quality indicator definition of a primary outcome was only based on what was 306 
described in the manuscript. It is possible that a primary outcome was defined retrospectively based on 307 
the observed data in a proportion of the studies. 308 
Concerns about the methodological quality of antimicrobial stewardship studies have been raised before, 309 
with several publications making recommendations to improve their scientific methods [16,24,26]. 310 
However, have found no improvement in methodological quality over time except for more frequent 311 
inclusion of sample size calculation and clinical outcomes. Therefore, there is still a need for clear 312 
recommendations to improve antimicrobial stewardship design quality. Recommendations for 313 
improvement should especially consider: (1) emphasizing the importance of choosing appropriate clinical 314 
and microbiological outcomes, (2) focusing on robust methods to evaluate stewardship interventions in 315 
the hospital setting. Implementing these recommendations in future antimicrobial stewardship studies will 316 
help in the optimal use of resources to determine which stewardship interventions are most effective to 317 
change clinical practice. Building on the work from the systematic review we established a working group 318 
of expert investigators in this field. This systematic review identifies the limitations in design features that 319 
are most important for validity and translation into clinical practice. The results will be used to formulate 320 
recommendations in a white paper that will support investigators with key design decisions, support 321 
funders assessing proposals for stewardship studies and enhance the quality and impact of research in 322 
this crucial area.  323 
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Figure 1. Flowchart of the studies included in the systematic literature review 338 
 339 
 340 
  341 
Table 1. Characteristics of included studies stratified by studies performed in the community and the 342 
hospital setting 343 
 
Study characteristics 
Community 
(n=205) 
n (%) 
Hospital 
(n=620) 
n (%) 
Number of patients included (median, IQR) 1255 (278-11230) 423 (186-1398) 
Number of centres involved (median, IQR) 27 (8-90) 1 (1-1) 
Age   
 Adults 64 (31) 285 (46) 
 Children 33 (16) 68 (11) 
 Both 108 (53) 267 (43) 
Specific disease targeted   
 No specific disease targeted 63 (31) 342 (55) 
 Upper respiratory tract infections 106 (52) 25 (4) 
 Lower respiratory tract infections 57 (28) 70 (11) 
 Bacteraemia 0 (0) 42 (7) 
 Urinary tract infections 18 (9) 27 (4) 
 Prophylaxis 2 (1) 39 (6) 
 Sepsis 0 (0) 17 (3) 
 Skin and soft tissue infections 1 (1) 8 (1) 
 Abdominal infections 3 (1) 10 (2) 
 Other 16 (8) 62 (10) 
Antibiotic class targeted   
 No specific antibiotic class targeted 177 (86) 427 (69) 
 Cephalosporins 4 (2) 66 (11) 
 Fluoroquinolones 10 (5) 54 (9) 
 Carbapenems 0 (0) 48 (8) 
 Vancomycin 0 (0) 31 (5) 
 Aminoglycosides 0 (0) 28 (5) 
 Penicillins 10 (5) 15 (2) 
 Macrolides 8 (4) 5 (1) 
 Other 17 (8) 89 (14) 
Antimicrobial stewardship interventions   
 Education 149 (73) 260 (42) 
 Audit and feedback – individual patient 12 (6) 245 (40) 
 Audit and feedback – periodic 59 (29) 82 (13) 
 Restriction 13 (6) 113 (18) 
 Clinical decision support 31 (15) 112 (18) 
 Rapid diagnostic testing 24 (12) 68 (11) 
 Therapeutic drug monitoring 0 (0) 15 (2) 
 Guideline implementation 20 (10) 95 (15) 
 Delayed prescribing 9 (4) 0 (0) 
 Other 42 (20) 78 (13) 
Research designs   
 Before-after study 48 (23) 365 (59) 
 Before-after study (ITS*) 22 (11) 82 (13) 
 Cohort without control group  6 (3) 75 (12) 
 Controlled before-after study 22 (11) 19 (3) 
 Randomised controlled trial (RCT) 28 (14) 40 (6) 
 Parallel cluster randomised trial 30 (15) 6 (1) 
 Parallel cluster randomised trial with baseline period 26 (13) 2 (1) 
 Controlled before-after study (ITS) 7 (3) 12 (2) 
 Non-randomised parallel cluster study 5 (2) 8 (1) 
 Factorial cluster randomised trial 7 (3) 0 (0) 
 Cluster randomised cross-over trial 2 (1) 3 (1) 
 Stepped wedge cluster randomised trial 0 (0) 1 (1) 
 Non-randomised cluster cross-over study 0 (0) 3 (1) 
 Factorial randomised controlled trial (RCT) 1 (1) 2 (1) 
 Non-randomised stepped wedge study 0 (0) 2 (1) 
 Adaptive RCT 1 (1) 0 (0) 
IQR: interquartile range, *ITS: interrupted time series  344 
Table 2. Outcomes reported in the included antimicrobial stewardship studies stratified by studies 345 
performed in the community and the hospital setting 346 
Process measure outcomes Community 
(n=205) 
n (%) 
Hospital 
(n=620) 
n (%) 
 Costs/cost-effectiveness 36 (18) 200 (32) 
 Appropriateness 34 (17) 178 (29) 
 Defined daily doses (DDD) 34 (17) 156 (25) 
 Proportion treated with antibiotics 121 (59) 131 (21) 
 Recommendation acceptance 6 (3) 114 (18) 
 Guideline adherence 27 (13) 100 (16) 
 Duration of treatment 5 (2) 93 (15) 
 Days on therapy (DOT) 6 (3) 62 (10) 
 Time to appropriate therapy 3 (1) 71 (11) 
 Antibiotic knowledge 17 (8) 14 (2) 
 None 2 (1) 5 (1) 
 Other 58 (28) 166 (27) 
Clinical outcome measures   
 None 144 (70) 283 (46) 
 Mortality 9 (4) 203 (33) 
 Length of stay 5 (2) 201 (32) 
 Infection 10 (5) 75 (12) 
 Hospital readmission 0 (0) 76 (12) 
 Adverse effects 5 (2) 52 (8) 
 Revisits 22 (11) 0 (0) 
 Clinical cure 12 (6) 27 (4) 
 Intensive care unit admission 0 (0) 24 (4) 
 Hospital admission 9 (4) 0 (0) 
 Time to clinical stability 3 (1) 6 (1) 
 Other 16 (8) 49 (8) 
Microbiological outcome measures   
 None 188 (92) 447 (72) 
 Colonization/infection resistant pathogens 17 (8) 146 (24) 
 Clostridium difficile infections 5 (2) 62 (10) 
 Other 2 (1) 12 (2) 
  347 
Table 3. Design quality features of the included studies stratified by studies performed in the community 348 
and the hospital setting 349 
Quality feature Community 
(n=205) 
n (%) 
Hospital 
(n=620) 
n (%) 
Randomised research design 95 (46) 55 (9) 
External control group 129 (63) 99 (16) 
Multicentre 148 (72) 101 (16) 
Sample size calculation reported 77 (38) 96 (15) 
Prospective data collection 144 (70) 288 (46) 
Correction for confounding factors 113 (55) 157 (25) 
Primary outcome defined 116 (57) 272 (44) 
Clinical outcome reported 61 (30) 337 (54) 
Microbiological outcome reported 17 (8) 173 (28) 
Sustainability assessed (≥12 months) 115 (56) 347 (56) 
 350 
 351 
  352 
Table 4. Results of stepwise backward selection of multivariable model containing all the factors with the different design quality indicators as 
outcome. The colours indicate either a strong negative association (OR<1.0) in red, or a strong positive association (OR>1.0) in green. Numbers 
indicate odds ratio’s with 95% confidence intervals 
 
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 Model 9 Model 10
Randomised 
design
External control
Sample size 
calculation
Prospective data
Confounding 
correction
Primary 
outcome
Clinical outcome
Microbiological 
outcome
Multicentre
Sustainability 
assessed
Clinical setting Community (n=205) 5.9 (3.8 - 9.2) 5.6 (3.6 - 8.5) 2.9 (1.9 - 4.5) 1.7 (1.2 - 2.6) 3.0 (2.1 - 4.3) 1.4 (1.0 - 2.0) 0.3 (0.2 - 0.5) 0.2 (0.1 - 0.4) 10.5 (7.1 - 15.7)
Financial support Yes (n=385) 4.7 (2.9 - 7.5) 4.1 (2.6 - 6.3) 3.1 (2.1 - 4.7) 2.2 (1.6 - 3.0) 2.5 (1.8 - 3.4) 1.8 (1.4 - 2.5) 1.9 (1.4 - 2.6) 3.0 (2.0 - 4.3)
Age group studied** Children (n=101) 1.1 (0.6 - 2.2) 0.8 (0.4 - 1.6) 0.8 (0.5 - 1.4) 1.1 (0.7 - 1.9) 1.0 (0.6 - 1.6) 0.6 (0.4 - 1.0) 1.4 (0.9 - 2.2)
Both (n=375) 0.6 (0.4 - 1.0) 0.6 (0.4 - 0.9) 0.4 (0.2 - 0.6) 0.5 (0.4 - 0.7) 0.5 (0.4 - 0.7) 0.4 (0.3 - 0.5) 1.6 (1.2 - 2.2)
Year study conducted*** 2005-2010 (n=160) 1.0 (0.5 - 1.9) 1.1 (0.6 - 1.9) 2.5 (1.3 - 4.8) 0.4 (0.2 - 0.6) 0.6 (0.4 - 1.0) 0.9 (0.6 - 1.5) 2.1 (1.2 - 3.7) 1.1 (0.7 - 1.8)
2011-2013 (n=156) 0.5 (0.3 - 1.1) 0.5 (0.2 - 0.9) 1.8 (0.9 - 3.5) 0.2 (0.1 - 0.3) 0.7 (0.4 - 1.2) 1.0 (0.6 - 1.6) 1.7 (1.0 - 3.0) 1.6 (1.0 - 2.5)
2014-2015 (n=173) 0.4 (0.2 - 0.8) 0.5 (0.2 - 0.9) 2.5 (1.3 - 4.9) 0.1 (0.1 - 0.2) 1.1 (0.7 - 1.8) 1.3 (0.8 - 2.1) 1.2 (0.7 - 2.1) 1.8 (1.1 - 2.8)
2016-2017 (n=176) 0.8 (0.4 - 1.5) 0.9 (0.5 - 1.7) 2.5 (1.3 - 4.9) 0.1 (0.1 - 0.2) 1.2 (0.7 - 1.9) 1.7 (1.0 - 2.7) 1.4 (0.8 - 2.4) 1.2 (0.8 - 1.8)
Geographical region**** Europe (n=260) 2.5 (1.5 - 4.2) 2.2 (1.4 - 3.5) 1.6 (1.1 - 2.5) 2.8 (1.9 - 4.1) 1.1 (0.8 - 1.5) 1.1 (0.8 - 1.6) 0.9 (0.6 - 1.4) 2.0 (1.3 - 3.1)
Asia (n=128) 2.6 (1.3 - 5.0) 2.4 (1.3 - 4.4) 1.1 (0.6 - 2.0) 1.7 (1.1 - 2.7) 0.4 (0.3 - 0.7) 1.8 (1.1 - 2.8) 1.2 (0.8 - 2.0) 1.0 (0.6 - 1.8)
Oceania (n=36) 1.6 (0.6 - 4.2) 1.5 (0.6 - 3.7) 0.5 (0.1 - 1.4) 1.8 (0.8 - 3.9) 0.5 (0.2 - 1.0) 0.5 (0.2 - 1.0) 0.2 (0.1 - 0.8) 0.9 (0.4 - 2.2)
Africa (n=29) 4.0 (1.1 - 14.5) 3.3 (0.9 - 11.8) 1.8 (0.5 - 5.8) 2.0 (0.6 - 6.2) 0.9 (0.3 - 2.5) 1.8 (0.6 - 5.3) 0.2 (0.1 - 1.7) 7.2 (2.0 - 25.1)
South America (n=17) 1.8 (0.4 - 7.4) 2.3 (0.6 - 8.4) 2.0 (0.6 - 6.5) 2.2 (0.8 - 6.4) 1.1 (0.4 - 2.9) 1.1 (0.4 - 3.0) 1.3 (0.4 - 3.8)
*Reference category: studies performed in the hospital setting (n=620), **Reference category: studies performed in adults (n=349), ***Reference category: studies performed before 2005 (n=160), ****Reference category: studies performed in North America (n=368)
Strong negative association Weak association Strong positive association
Design quality indicators
Factors
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SUPPLEMENT 
Table S1. Definition of the design quality determinants used and corresponding categorisation if 
applicable 
Design quality 
indicator 
Definition Categorisation (if applicable) 
Randomised research 
design 
Allocation of the antimicrobial stewardship 
intervention or comparator was random. 
Randomisation is defined as control by 
means of random allocation at any level 
(individual or cluster). 
Randomised:  
RCT, c-RCT, cx-RCT, sw-CRT 
Non-randomised: 
BA(with or without ITS 
analysis), cBA, cohort studies, 
non-randomised trials 
External control group The outcome was also assessed in an 
external control group without antimicrobial 
stewardship intervention. External indicates 
that a contemporaneous cluster or group was 
included in which the intervention under 
study is not implemented. 
Parallel control group:  
cBA, RCT, non-randomised 
trials, c-RCT, cx-RCT, sw-CRT 
No parallel control group:  
BA, cohort studies 
Number of centres Amount of centres involved in the study, 
either as control or intervention. 
Single centre: 0-1 centre 
 
Multicentre: >1 centre 
Sustainability of the 
intervention 
sufficiently assessed 
The duration of follow-up of the cluster after 
the intervention was introduced to assess the 
sustainability of the intervention 
Yes: 
Duration of follow-up ≥12 
months 
No:   
Duration of follow-up <12 
months 
Sample size 
calculation reported 
A sample size calculation was performed to 
ensure sufficient power for the primary 
outcome.  
- 
Prospective data 
collection 
The data was prospectively collected. If not 
reported we assumed the data collection to 
be retrospective. 
- 
Confounding 
correction 
The intervention effect was corrected for 
confounding bias, either by randomisation, 
matching, stratification or correction.  
- 
Primary outcome A primary outcome was clearly defined. - 
defined 
Clinical outcome 
reported 
Any clinical outcome was reported. Clinical 
outcomes include mortality, length of stay, 
readmissions, revisits, etc. 
- 
Microbiological 
outcome reported 
Any microbiological outcome was reported. 
Microbiological outcomes include CDI, 
colonisation or infection with antimicrobial 
resistant bacteria 
- 
RCT: randomised controlled trial, c-RCT: parallel cluster randomised controlled trial, cx-RCT: cluster 
cross-over randomised controlled trial, sw-CRT: stepped wedge cluster randomised trial, BA: before-after 
study, cBA: controlled before-after study, ITS: interrupted time-series, CDI: Clostridium difficile infection 
  
Table S2.  Design quality features changes over time of the included studies stratified by studies 
performed in the community and the hospital setting 
 
Hospital 
 
 
1977-2004 
 
2005-2010 
 
2011-2013 
 
2014-2015 
 
2016-2017 
Randomised design 10% 17% 6% 6% 8% 
External control 12% 20% 6% 8% 11% 
Sample size calculation 8% 21% 13% 18% 17% 
Multicentre 9% 14% 18% 20% 18% 
Prospective data 71% 68% 37% 36% 31% 
Confounding correction 24% 22% 19% 29% 30% 
Primary outcome 38% 50% 37% 45% 48% 
Clinical outcome 43% 51% 50% 58% 66% 
Microbiological outcome 21% 38% 32% 23% 27% 
Sustainability assessed 53% 50% 55% 65% 54% 
 
Community 
 
     
Randomised design 43% 47% 41% 41% 61% 
External control 45% 51% 41% 45% 65% 
Sample size calculation 19% 44% 35% 48% 52% 
Multicentre 68% 75% 78% 69% 71% 
Prospective data 89% 65% 57% 59% 74% 
Confounding correction 58% 42% 54% 66% 65% 
Primary outcome 53% 53% 59% 66% 58% 
Clinical outcome 32% 29% 27% 31% 29% 
Microbiological outcome 6% 5% 8% 17% 10% 
Sustainability assessed 43% 56% 78% 55% 52% 
  
Figure S1. Design quality indicators stratified by factors: (A) community versus hospital setting, (B) 
financial support versus no financial support, (C) age setting: children, adults or both, (D) old versus new 
studies, (E) geographical region 
 
 
  
  
  
  
